共 15 条
[1]
Inhibition of proliferation of human smoothmuscle cells by various HMG- Co A reductaseinhibitors;comparison with other human celltypes. Negre- Aminou P,van Vliet AK,van Erck M,etal. Biochimica et Biophysica Acta . 1997
[2]
Reduction of L DL cholesterol by2 5 % to60 % inpatients with primary hypercholesterolemia byatorvastatin,a new HMG- Co A reductase in-hibitor. Nawrocki JW,Weiss SR,Davidson MH,et al. Arteriosclerosis and Thrombosis . 1995
[3]
Reduction of L DL cholesterol by2 5 % to60 % inpatients with primary hypercholesterolemia byatorvastatin,a new HMG- Co A reductase in-hibitor. Nawrocki JW,Weiss SR,Davidson MH,et al. Arteriosclerosis and Thrombosis . 1995
[4]
Ator-vastatin and simvastatin reduce elevated choles-terol in non- insulin dependent diabetes. Best JD,Nicholson GC,O′Neal DN,etal. DiabetesN utr Metab . 1996
[5]
Multiple- dose pharmacokinetics,pharmaco-dynamics,and safety of atorvastatin,an inhibitorof HMG- Co A reductase,in healthy subjects. Cilla DD Jr,Whitfield L R,Gibson DM,et al. Clinical Pharmacology and Therapeutics . 1996
[6]
Effects of atorvastatin,an HMG- Co A reductaseinhibitor,on hepatic oxidative metabolism ofantipyrine. Yang BB,Hounslow NJ,Sedman AJ,et al. Journal of Clinical Pharmacology . 1996
[7]
Atherosclerosis[P]. DONG CHUNMING;GOLDSCHMIDT PASCAL J.中国专利:US2008095751A1,2008-04-24
[8]
Efficacy and safety of a new HMG- Co Areductase inhibitor,atorvastatin,in patients withhypertriglyceridemia. Bakker- Arkema RG,Davidson MH,GoldsteinRJ,etal. The Journal of The American Medical Association . 1996
[9]
Com-parison of one- year efficacy and safety of atorvas-tatin versus lovastatin in primary hypercholes-terolemia.Atorvastatin Study Group I. Davidson M,Mc Kenney J,Stein E,et al. American Journal of Chinese Medicine . 1997
[10]
A quarter cen-tury of drug treatment of dyslipoproteinemia witha focus on the new HMG- Co A reductase inhibitorfluvastatin. L evy RI,Troendle AJ,Fattu JM. Circulation . 1993